Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dornase Alfa in COVID-19 ARDS
NCT04355364Phase 3Terminated
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dornase alfa in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Adolphe de Rothschild Foundation Hospital. Started Apr 2020; status: terminated.
02
Drugs
dornase alfa
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04355364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355364.